Immunomodulating effects of aqueous and methanol extracts of Jatropha curcas L. on haematological indices in Schistosoma haematobium – infected mice
0
Citation
0
Reference
10
Related Paper
Abstract:
The haematological indices of S. haematobium – infected Swiss Albino micewere monitored to evaluate the immunomodulatory activities of aqueous(AJc) and methanol (MJc) extracts of Jatropha curcas (L.) at preâ€Âinfectionpost â€Âinfection and postâ€Âtreatment. There was a nonâ€Âsignificant decrease(p>0.05) in the weight of mice in all the groups. However, there was significantincrease ( p < 0.05) in the total white blood cell counts, neutrophils andlymphocytes for group I (AJc) and group II (MJc) in S. haematobium †infectedmice. There was no relationship between the level of eosinophils in thetreated mice. No significant change in the haematological indices was observedin the group which was administered the standard drug †Praziquantel(PZQ). The immunomodualting effects of aqueous and methanol extracts ofJatropha curcas Schistosoma haematobium†††infected mice.when compared to PZQ are promising in immunosuppressedKeywords:
Jatropha curcas
An 8-year-old, Senegalese boy presented with a history of painless macroscopic haematuria. The diagnosis schistosomiasis was made, based on the urine sediment that revealed eggs from the trematode parasite Schistosoma haematobium. The patient was treated with praziquantel and made a full recovery.
Schistosoma
Cite
Citations (0)
Chemotherapy with praziquantel (PZQ) is the mainstay of schistosomiasis control. However, there are recent concerns about tolerance or resistance to PZQ, so that monitoring its efficacy in different settings is required.A longitudinal study was conducted to evaluate the impact of PZQ for the treatment of Schistosoma haematobium infection among schoolchildren at Al Salamania, Central Sudan. Parasitological examinations for S. haematobium were performed in a cohort of schoolchildren (6-15 years of age) before and 1 year after treatment with a single dose of PZQ 40 mg/kg.Out of 562 (309 boys and 253 girls) schoolchildren recruited from three elementary schools, 420 completed one longitudinal dataset that comprised of data from two time points; baseline, and follow-up 1 year after treatment with a single dose of PZQ 40 mg/kg for S. haematobium infection. A single dose of PZQ significantly reduced the prevalence of S. haematobium infection by 83.3% (from 51.4% to 8.6%) and the geometric mean intensity of infection of positive individuals by 17.0% (from 87.7 to 72.8 eggs/10 ml of urine) 1 year after treatment. While there was no significant difference in the reduction of the prevalence of S. haematobium infection between the gender or age groups, there was a significantly higher reduction of intensity of S. haematobium infection among girls in comparison with boys.There was a significant reduction of S. haematobium infection 1 year after PZQ treatment in this setting.
Longitudinal Study
Tropical Medicine
Cite
Citations (50)
Schistosomiasis remains a parasitic infection of public health importance especially in Africa south of the Sahara including Cameroon. Chemotherapy using praziquantel has been the most effective and widespread control measure used. However, there are reports of reduced efficacy of the drug. The aim of this study was to assess the efficacy and safety of praziquantel against Schistosoma haematobium among infected individuals in the Ikata-Likoko area of southwest Cameroon. Following a baseline study, S. haematobium egg load was determined using the urine filtration technique and microscopy. Participants were treated with a unique dose of praziquantel of 40 mg/Kg body weight. A control test was carried out on the 42nd day post-treatment to determine the proportion of positive participants with viable eggs (cure rate) and the egg loads. The egg loads obtained during the control and at baseline were used to calculate the egg reduction rate (ERR) used as the main indicator of praziquantel efficacy according to the WHO, 2013 protocol.At baseline, the prevalence of S. haematobium was 34.3% (177/516). Out of these a total of 174 participants aged between 4 and 76 years were recruited into the study. A total of 130 participants came for follow up on day 42. Among them, 22.3% (29) were positive for eggs of S. haematobium but none of the eggs were viable giving a cure rate of 100%. The overall mean egg load per 10 mL (MEL/10 mL) of urine reduced from 31 (1-400) at baseline to 6.0 (1-35) on day 42. The overall ERR was reduced (80.3%). However, the efficacy was satisfactory (ERR ≥ 90%) in females, children ˂ 5 years, and some localities and for individuals with heavy infection intensity. Fifteen (8.6%) of the participants presented minor adverse events including abdominal disorders, headache and vomiting but did not last for more than 24 h.Treatment with praziquantel was efficacious and safe showing reduction in prevalence as well as mean egg load in some individuals with few adverse events recorded. The distribution of praziquantel in the area should be extended to other age groups and not just school-age children. A study with multiple drug doses and longer period of evaluation could reveal more information on praziquantel efficacy in the area.
Schistosoma
Cite
Citations (4)
Introduction: Urinary schistosomiasis caused by Schistosoma haematobium is common in some parts of Lusaka Province, Zambia, where water contact activity is high and sanitation is poor. We conducted a longitudinal study in Ng'ombe Compound of Lusaka, between 2007 and 2015, to observe the prevalence and intensity of S. haematobium infection among community primary school children, before and after receiving a single dose of praziquantel.Materials and Methods: A total of 975 (445 females and 530 males) pupils, aged 9–16 years, were tested for S. haematobium at baseline. After mass treatment with praziquantel in 2010, 1570 pupils (785 females and 785 males), aged 9–15 years, were examined for S. haematobium eggs, from 2011 to 2015.Results: At baseline, 279 out of 975 of the children were infected, with light infections constituting 84.9% and 15.1% classified as heavy infection. After mass treatment with praziquantel, the prevalence rate dropped, slightly, to 20.3% (63 out of 310) in 2011. However, it increased the following years up to 38% (133 out of 350) in 2015, with prevalence rates higher in males than females. The average number of heavy infection cases increased to 24.3% (120 out of 494) after treatment, reducing cases of light infections to 75.7% (374 out of 494).Conclusion: This study revealed that mass treatment with a single dose of praziquantel was not sufficient to significantly reduce the transmission of schistosomiasis. Further studies will need to evaluate whether multiple praziquantel treatments will be more therapeutically effective in limiting future incidences.
Mass drug administration
Schistosoma
Cite
Citations (13)
A systematic analysis of the existing literature has been undertaken to compare the therapeutic and operational profiles of metrifonate (CAS 52-68-6), and praziquantel (CAS 55-268-74-1), two anti-schistosomal compounds. The criteria evaluated were therapeutic efficacy against Schistosoma haematobium and other helminths, impact on pathology commonly associated with S. haematobium infection, frequency, type and duration of adverse reactions, health risk associated with inadvertent overdosage, applicability and practicality of treatment in various medical settings, tolerance and resistance, pharmacological properties, toxicity and economic aspects. It is concluded that both medical and operational criteria indicate that praziquantel is superior to metrifonate for the treatment of schistosomiasis caused by S. haematobium. Since, compared to praziquantel, metrifonate has a number of disadvantages, future antischistosomal chemotherapy can do without this drug.
Pharmacotherapy
Cite
Citations (33)
Abstract. A substantial portion (63%) of circulating schistosomal antigen was cleared from the serum of hyperinfected mice within 72 hours after treatment with the helminthocide, praziquantel. This result suggests that circulating antigen may be a diagnostically useful marker for active schistosomiasis.
Clearance
Cite
Citations (7)
Abstract Background Praziquantel is the drug of choice in preventive chemotherapy targeting schistosomiasis. Increasing large-scale administration of praziquantel requires monitoring of drug efficacy to detect early signs of development of resistance. Standard protocols for drug efficacy monitoring are necessary. Here, we determined the optimal time point for praziquantel efficacy assessment against Schistosoma haematobium and studied the dynamics of infection parameters following treatment. Methods Ninety school-aged children from south Côte d’Ivoire with a parasitologically confirmed S. haematobium infection were treated with a single oral dose of praziquantel (40 mg/kg) and followed up for 62 days post-treatment. Urine samples were collected on 23 schooldays during this period and were subjected to visual examination (macrohaematuria), urine filtration and microscopy ( S. haematobium eggs) and reagent strip testing (microhaematuria, proteinuria and leukocyturia). Results Observed cure and egg reduction rates were highly dependent on the time point post-treatment. Egg reduction rates were high (>97%) in weeks 3–9 post-treatment. Cure rates were highest in weeks 6 (92.9%) and 9 (95.0%) post-treatment. The prevalence of infection-associated parameters decreased after treatment, reaching a minimum of 2.4% in weeks 5 (proteinuria) and 7 (leukocyturia) post-treatment, and 16.3% at the end of week 8 (microhaematuria). Macrohaematuria disappeared between weeks 3 and 6 post-treatment. Conclusions For monitoring praziquantel efficacy against S. haematobium , we recommend that the cure rate is assessed at week 6 post-treatment. The egg reduction rate can be evaluated earlier, from day 14 post-treatment onwards. Reagent strips are a useful additional tool for evaluating treatment outcomes in areas with high endemicity, preferably at weeks 5 and 6 post-treatment. The delayed decrease of microhaematuria confirms that lesions in the urinary tract persist longer than egg excretion post-treatment.
Efficacy
Cite
Citations (53)
Schistosoma
Cite
Citations (52)
Nineteen cases of acute schistosomiasis patients whose temperatures had fallen to normal automatically were treated with praziquantel, and their temperatures recrudesced after the treatment. Then they were treated with larger dose of praziquantel according to the scheme of acute schistosomiasis therapy, and all of them were cured.
Falling (accident)
Cite
Citations (1)
We examined the long-term efficacy of praziquantel against Schistosoma haematobium, the causative agent of urinary schistosomiasis, during a school-based treatment program in the Msambweni area of Coast Province, Kenya, where the disease is highly endemic. Our results, derived from treating 4,031 of 7,641 children from 1984 to 1993, indicate substantial year-to- year variation in drug efficacy. However, the pattern of this variation was not consistent with primary or progressive emergence of praziquantel resistance. Mathematical modeling indicated that, at current treatment rates, praziquantel resistance will likely take 10 or more years to emerge.
Schistosoma
Cite
Citations (108)